title: Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.
abstract: OBJECTIVE
  This study was designed to investigate whether a preventive weight management program (WMP) reduces weight gain during olanzapine (OLZ) treatment. Moreover, we examined the effects of intervention on metabolic parameters.
  
  
  METHODS
  Patients (N = 100) with schizophrenia or schizoaffective disorder (DSM-IV) who had commenced treatment with OLZ were recruited. Following a run-in period of 4 weeks, 74 patients who had gained at least 1.5 kg body weight were randomized to receive either 12 bi-weekly WMP sessions (prevention group (PG), n = 36), or usual care (control group (CG), n = 38). Anthropometric and metabolic parameters were assessed after the 24-week intervention phase and a 24-week follow-up.
  
  
  RESULTS
  Forty-two percent of 74 participants (PG: 36.1%, CG: 47.4%) finished the 24-week intervention phase while 34% of them (PG: 30.6%, CG: 36.8%) completed the 48-week study. There was no significant difference in weight gain between groups (PG: + 3.4 ± 4.2 kg vs. CG: + 4.5 ± 6.1 kg, P = 0.184) after 24 weeks. Nevertheless, PG showed a significantly smaller increase in waist circumference than CG (PG: + 4.6 ± 8.3 cm, CG: + 10.1 ± 7.3 cm, P = 0.019) after 48 weeks. Furthermore, PG showed a significantly smaller increase in fasting glucose (P = 0.031) and 2-h glucose after oral glucose load (P = 0.018) than CG.
  
  
  CONCLUSIONS
  These results suggest that preventive WMP may reduce the risk of abdominal obesity and deterioration of glucose metabolism in OLZ-treated patients.
authors: Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Duesseldorf , Germany.
authors: Joachim
authors: J
authors: Cordes
authors: Johanna
authors: J
authors: Thünker
authors: Gunnar
authors: G
authors: Regenbrecht
authors: Jürgen
authors: J
authors: Zielasek
authors: Christoph U
authors: CU
authors: Correll
authors: Christian
authors: C
authors: Schmidt-Kraepelin
authors: Christian
authors: C
authors: Lange-Asschenfeldt
authors: Marcus W
authors: MW
authors: Agelink
authors: Kai G
authors: KG
authors: Kahl
authors: Wolfgang
authors: W
authors: Gaebel
authors: Ansgar
authors: A
authors: Klimke
authors: Hans
authors: H
authors: Hauner
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D001786:Blood Glucose; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000517:prevention & control*; D050171:Dyslipidemias / Q000139:chemically induced / Q000517:prevention & control*; D061345:Early Medical Intervention; D005260:Female; D018149:Glucose Intolerance / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced / Q000517:prevention & control*; D000077152:Olanzapine; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*; D061217:Weight Reduction Programs / Q000379:methods*
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D001569:Benzodiazepines; D000077152:Olanzapine